Skip to Content

Cosmegen (dactinomycin) Disease Interactions

There are 5 disease interactions with Cosmegen (dactinomycin):

Major

Dactinomycin (applies to Cosmegen) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

The use of dactinomycin is contraindicated in patients with known or suspected varicella-zoster or herpes zoster infections. A severe, generalized, potentially fatal disease has been reported with dactinomycin use during or about the time of such infections. In addition, dactinomycin can induce myelosuppression, particularly when used with X-ray therapy. Therefore, dactinomycin therapy should be withheld, or given cautiously, in patients with an infection, depending on the severity. Close clinical monitoring of hematopoietic function is recommended whenever the drug is administered. If white blood cell and/or platelet counts are markedly decreased, therapy should be withheld to allow marrow recovery, which often takes up to three weeks.

References

  1. "Product Information. Cosmegen (dactinomycin)." Merck & Co, Inc, West Point, PA.
Moderate

Dactinomycin (applies to Cosmegen) hepatic toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatotoxicity can occur with the use of dactinomycin for injection. Monitor AST, ALT, alkaline phosphatase, and bilirubin prior to and during dactinomycin therapy. Caution is advised if used in patients with preexisting liver disease.

Moderate

Dactinomycin (applies to Cosmegen) live viral vaccines

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vaccination

The safety with live viral vaccines following dactinomycin for injection has not been studied and vaccination with live virus vaccines is not recommended before or during treatment.

Moderate

Dactinomycin (applies to Cosmegen) myelosuppression

Moderate Potential Hazard, High plausibility. Applicable conditions: Fever, Bone Marrow Depression/Low Blood Counts, Bleeding

Severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia and anemia, can occur with dactinomycin. If either the white blood cell or platelet count is markedly decreased, therapy with dactinomycin should be withheld or dose should be reduced to allow recovery. Therapy with dactinomycin should be administered cautiously in patients with myelosuppression. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Cosmegen (dactinomycin)." Merck & Co, Inc, West Point, PA.
Moderate

Dactinomycin (applies to Cosmegen) renal toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Abnormalities of renal function can occur with dactinomycin for injection. Monitor creatinine and electrolytes frequently during dactinomycin therapy. Caution is advised if used in patients with preexisting renal disease.

Cosmegen (dactinomycin) drug interactions

There are 179 drug interactions with Cosmegen (dactinomycin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.